1-Pyrrolidin-1-yl-2-[3-(1,3-thiazol-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]ethanone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并哒嗪类
• 英文名称: 1-Pyrrolidin-1-yl-2-[3-(1,3-thiazol-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]ethanone
• 英文别名: 1-pyrrolidin-1-yl-2-[3-(1,3-thiazol-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]ethanone
• 化学式: C₁₄H₁₄N₆OS
• 分子量: 314.37
• InChiKey: HOIITRBWARQFDZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  105
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• TRIAZOLOPYRIDAZINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF
  申请人：Southern Research Institute

  公开号：EP2844660A1

  公开（公告）日：2015-03-11
• [EN] TRIAZOLOPYRIDAZINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF<br/>[FR] COMPOSÉS DE TRIAZOLOPYRIDAZINE, UTILISATION COMME INHIBITEURS DE LA KINASE LRRK2, ET PROCÉDÉS POUR LEUR PRÉPARATION
  申请人：SOUTHERN RES INST

  公开号：WO2013166276A1

  公开（公告）日：2013-11-07

  The present invention provides novel LRRK2 kinase inhibitors and methods of treating disease states using these inhibitors. Certain triazolopyridazine compounds have been discovered according to the present disclosure that inhibit LRRK2, and therefore find utility in the treatment of a number of disorders neurodegenerative diseases such as Parkinson's disease; precancerous conditions and cancer; autoimmune disorders such as Crohn's disease, rheumatoid arthritis and psoriasis; and leprosy.